uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results.
We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases.
uniQure Presents Updated Clinical Data in Patients with Severe Hemophilia B Demonstrating up to 9 Months of Sustained Levels of Factor IX Activity and Therapeutic Effect
uniQure Announces Oral Presentation of Updated Results for AMT-060 at the World Federation of Hemophilia (WFH) 2016 World Congress
uniQure Appoints Jonathan Garen as Chief Business Officer
uniQure Appoints Maria E. Cantor as Senior Vice President, Investor Relations & Communications